Please assess the completion status of the following clinical trial:

Trial Title: A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~●≥ 18 and ≤ 70 years of age.~* ECOG performance status of 0-1.~* Metastatic breast cancer, confirmed by histological analysis.~* Have experienced at least 1 and at most 4 regimens, and failed from the last chemotherapy regimen. Pretreated anthracycline, taxanes and capecitabine (any rational reason for no use of capecitabine is acceptable) are mandatory.~* Women diagnosed with human epidermal growth factor receptor positive (HER2+) should have failed for at least 1 anti-HER2 therapy (any rational reason for no use of anti-HER2 therapy is acceptable). HER2+ is defined as +++ staining on immunohistochemistry or FISH/CISH positive for gene amplification.~* Women diagnosed with HR+ should have failed for at least 1 hormonal therapy.~* Have failed for at least one chemotherapy regimen, but at most three regimens(including adjuvant and neo-adjuvant setting).~* Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).~* Have at least one extracranial measurable site of disease according to RECIST 1.0 criteria that has not been previously irradiated.~* Life expectancy of more than 3 months.~* Negative serum or urine pregnancy test taken in all women within 7 days before inclusion. Sexually active women of childbearing potential must use a medically acceptable form of contraception from the beginning of the study to 8 weeks after the last dose of the investigated drug.~* Written informed consent prior to study specific screening procedures.~Exclusion Criteria:~* Triple-negative breast cancer (ER-, PR- and HER2-. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification. )~* Pregnant or lactating women.~* Less than 4 weeks from the last clinical trial.~* Uncontrolled hypertension with mono-drug therapy (\>140/90 mm Hg)；ischemia of the myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF \> 470ms for female patients） or New York Heart Association Class III/IV~* Any factors that influence the usage of oral administration.~* The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300 mg/m2 and 600 mg/m2, respectively.~* Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is less than 4 weeks (Duration for nitroso or mitomycin is less than 6 weeks).~* Confirmed brain metastasis.~* Inadequate hepatic, renal, heart, and hematologic functions (hemoglobin \<90g/L, neutrophils \< 1.5×10\^9/L, platelets \< 80×10\^9/L , ALT \> 2.5 x upper limit of normal (ULN)(5x for liver metastasis), AST \> 2.5 x ULN (5x for liver metastasis), serum bilirubin \> 1.5 x ULN, serum creatine \> 1.0 x ULN, creatinine clearance rate ≤ 50ml/min, LVEF \< lower limit of normal (LLN).~* Abnormal coagulative function, inclined to bleeding or is receiving thrombolytictherapy or anticoagulation.~* History of arterial/venous embolic events (such as cerebrovascular accident, TIA, deep vein thrombus,and pulmonary embolism)~* Unhealed wound (\> 30 days) or bone fracture.~* Urine protein ≥++ and confirmed \>1.0 g by the 24h quantity.~* Previous or present history of pulmonary fibrosis,interstitial pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or greatly-impaired pulmonary function.~* Disability of serious uncontrolled intercurrence infection.~* Abuse of alcohol or drugs.~* Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is permitted).~* Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.~* The active HBV or HCV infection or HBV DNA ≥10\^4/ml.~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.~* Presence of serious harm to subjects or complication to hinder the completion of the study judged by investigators

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): Apatinib 500mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete